Located in Couvet, Switzerland, Bristol Myers Squibb’s manufacturing facility will be Wuxi STA’s first plant in Europe. On completion of the deal, Wuxi STA is expected to acquire the Couvet site’s operations and assets.
CPhI’s new report predicts a positive outlook for the pharma manufacturing supply chain in 2021 and highlights that the most immediate trend will be to witness some degree of ‘vaccine nationalism’ in the background of the initial stage of global Covid-19 vaccines roll-out before scale-up is achieved.
Sirio has established the first smart factory in the nutraceuticals industry in Ma’anshan, China. The next-gen facility will make use of automation, Internet of Things and artificial intelligence to ensure a high level of process control as well as superior quality standards for producing nutraceuticals.
According to the CPhI Annual Report, the growth of contract manufacturing organisations (CMOs) has been curbed due to innovator drug approvals from mega cap pharma companies. However, the demand for contract clinical and recombinant vector manufacturing is growing.
Sirio Europe has invested in advanced manufacturing and green technologies for its Brandenburg facility in Germany. With the incorporation of these solutions, the company aims to substantially increase its CDMO production capacity as well as energy efficiency.
The recent CPhI Pharma Index survey has revealed the significance of finding new international partners and improving supply chain contingencies for global pharma executives in the background of the Covid-19 pandemic.
Amidst the global pandemic of Covid-19, travel restrictions have been imposed across the globe. In these difficult times, CPhI & P-Mec China will be hosting a unique Virtual Expo Connect from June 18-24, 2020 for its exhibitors and attendees.
The Xcelerate Integrated Solutions platform by Piramal Pharma Solutions stands out for its speed, flexibility, and versatility. The solution is also backed by a track record of over 70 recent programmes, with investments in systems and capabilities, for a seamless customer experience.
Based on last year’s sales, Saudi Arabia remains the biggest pharma market in the region followed by Turkey, Egypt and the UAE. Across the MENA region, the total pharma sales have reached 32 billion dollars.